Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Standard Chartered Expands Hedge Fund Access for Wealth Clients 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
Baidu Shares Sink to One-Year Low as Ad Weakness Overshadows AI Growth 
Add as a preferred source on Google
NEW HAVEN, Conn., May 04, 2018 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Joseph Truitt, President and Chief Executive Officer of Achillion, will present a corporate overview at the Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8, 2018, at 9:20 a.m. ET at the Intercontinental Boston Hotel, Boston, MA.
The live audio and subsequent archived webcasts of the Company's presentations will be accessible from the Company's investor relations website, http://ir.achillion.com. The audio recording will be archived for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a science-driven, patient-focused company seeking to leverage its capabilities across the continuum from discovery to commercialization in its goal of providing better treatments for people with serious diseases. The company employs a highly-disciplined discovery and development approach that has allowed it to build a platform of potent and specific complement factor D inhibitors for AP-mediated diseases. Achillion is rapidly advancing its efforts to become a fully-integrated pharmaceutical company with a goal of bringing life-saving medicines to patients with rare diseases. More information is available at http://www.achillion.com.
Investors & Media: Glenn Schulman, PharmD, MPH Achillion Pharmaceuticals, Inc. Tel. (203) 752-5510 [email protected]
